Figure 7F shows the selected compounds targeting this pathway, and NPC268 is the most sensitive cell line among all NPC lines. Although the AKT1 E17K mutation is rarely reported in NPC (0.6% in a Southern China NPC cohort; ref. 58), this mutation has been used as a biomarker in several clinical trials of AKT inhibitors in solid tumors (AZD5363-Capivasertib, ARQ 092; refs. 52, 59, 60), with an objective response rate of 28.6% reported for metastatic tumors with AKT1 E17K mutation in the NCI-MATCH Subprotocol EAY131-Y trial (52). This evidence concerns the gene AKT1 and metastatic neoplasm.